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Abstract
Mitochondria are the most complex and the most important organelles of eukaryotic cells, which are involved in
many cellular processes, including energy metabolism, apoptosis, and aging. And mitochondria have been
identified as the “hot spot” by researchers for exploring relevant associated dysfunctions in many fields. The
emergence of comparative proteomics enables us to have a close look at the mitochondrial proteome in a
comprehensive and effective manner under various conditions and cellular circumstances. Two-dimensional
electrophoresis combined with mass spectrometry is still the most popular techniques to study comparative
mitochondrial proteomics. Furthermore, many new techniques, such as ICAT, MudPIT, and SILAC, equip researchers
with more flexibilities inselecting proper methods. This article also reviews the recent development of comparative
mitochondrial proteomics on diverse human diseases. And the results of mitochondrial proteomics enhance a
better understanding of the pathogenesis associated with mitochondria and provide promising therapeutic targets.
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Introduction
Mitochondria, which are mainly composed by proteins
and lipids, are considered as the most complex and the
most important organelles of eukaryotic cells. They not
only play a leading role in the energy metabolism, but
are also closely involved in many cellular processes.
Furthermore, mitochondria have a manageable level of
complexity as a consequence of their apparent prokaryo-
tic ancestry. Their endosymbiotic origins have been well
preserved in their double membrane structure, and they
possess their own circular genome with mitochondria-
specific transcription, translation, and protein assembly
systems [1]. Based upon the human genome, there is
estimated to be approximately 2000 to 2500 mitochon-
drial proteins [2], however, just over 600 have been
identified at the protein level [3]. For this reason, mito-
chondria contain a great number of proteins that have
yet to be identified and characterized.
Due to the fact that proteins are the carriers of biotic
movement, the mitochondrial proteome is deemed as an
ideal target for global proteome analysis. In the past,
many effects of disease processes in which mitochondria
are involved have been studied using classic biochemical
methods [4]. However, these studies usually focus on
only one particular protein, but not on the whole mito-
chondrial proteome. Recent developments in proteomics
have allowed more in-depth studies of proteins. Proteo-
mics is the large-scale study of all proteins in an organ-
ism and allowes a global insight into the abundance of
protein expression, localization, and interaction. Com-
bining genomics, mass spectrometry, and computation,
it is possible to systematically identify the mammalian
mitochondrial proteome. The proteome is often used to
investigate the pathogenesis, cellular patterns, and func-
tional correlations on protein levels in a non-biased
manner [5]. This proteomic approach also allows the
possibility for developing new candidate biomarkers for
the diagnosis, staging and tracking of disease. Compara-
tive proteomics is a subset of proteomics whose primary
purpose is revolving around the following fields: the
investigation of the pathogenesis and mechanism of a
drug, the discovery of new targets for diagnosis and
treatment, and the examination of the effects of envir-
onmental factors on soma and cells. Thus, many signifi-
cant proteins have been identified from normal and
abnormal individuals often under various states treated
by some agents. Researchers have made tremendous
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expressed proteins in the subcellular organelle. By doing
so, the diversity of proteins can be unmasked and reveal
the subcellular location information. Therefore, owing
to the significant roles and functions in the cell, mito-
chondria have become a research “hot spot” in subcellu-
lar proteomics. With these new techniques, a thorough
investigation of comparative mitochondrial proteomics
becomes more and more achievable. Mitochondrial pro-
teomic profiles have been generated across multiple
organs, including brain, heart, liver, and kidney [6-8].
This review presents a summary of progression of the
mitochondrial proteome in various human diseases
using comparative proteomic techniques reported in
recent years. Future prospects and challenges for the
mitochondrial proteome will also be discussed.
Techniques in comparative proteomics of
mitochondria (both gel-based and gel-free)
Gel-Based Techniques
Two-dimensional gel electrophoresis (2-DE) combined
with mass spectra is still the most popular gel-based
proteomic technique for comparative proteomics nowa-
days and has matured significantly over the past decades
[9]. The most frequently used method is termed “bot-
tom-up proteomics,” which is a strategy using mass
spectrometry or tandem mass spectrometry (MS/MS) to
analyze proteolytically digested proteins [10]. Peptide
mass fingerprinting (PMF) of digested peptide fragments
using matrix-assisted laser desorption/ionization time of
f l i g h t( M A L D I - T O F )i st h ep r e f e r r e dm e t h o df o ra n
initial protein identification after separation by 2-DE
due to its high throughput and cost efficiency [11].
However, 2-DE has many shortcomings in separating
certain protein classes, such as membrane proteins, high
molecular weight (> 200 kDa) or small molecularweight
proteins (< 10 kDa), and basic proteins, ect. The appli-
cation of 2-DE to study the mitochondrial proteome has
its owndisadvantages [12,13]. Two-dimensional fluores-
cence difference gel electrophoresis (2D-DIGE) is the
development of 2-DE that was originally introduced by
Minden [14]. It also allows for the direct comparison of
the changes in protein abundance changes, which is less
than 10% across samples simultaneously with a 95% sta-
tistical reliability coefficient without interference due to
gel-to-gel variation [15]. Moreover, another technique
named BNPAGE (blue native gel electrophoresis)
invented by Shägger and Jagow, is specialized for separ-
ating intact membrane protein complexes [16]. It has
been primarily used to separate and isolate the five
multi-polypeptide complexes of the oxidative phosphor-
ylation (OXPHOS) system and the recovery of all
respiratory chain complexes are approaching the level of
detection [17].
Non-Gel Based Techniques: MudPIT and ICATs
Multi-dimensional protein identification technology
(MudPIT) combines the resolving power of high perfor-
mance liquid chromatography (HPLC) with the analyti-
cal capacity of tandem mass spectrometry (MS/MS).
Using this method, a complex protein mixture is first
digested with a protease resulting in an even more com-
plex peptide mixture that is resolved by multidimen-
sional HPLC. As the peptides are eluted off of the
column, they are analyzed by mass spectrometry. Yates
et al introduced this automated multidimensional pro-
tein identification technology termed “shotgun” proteo-
mics and demonstrated that a dynamic range of 10,000
to 1 between the most abundant and least abundant
proteins/peptides in a complex peptide mixture could
be identified [18]. MudPIT overcomes the shortcomings
of mass spectrometry such as deficiencies in detecting
proteins with extreme alkalinity, hydrophobicity, and
maximum or minimum molecular mass. However, Mud-
PIT cannot yet accomplish absolute quantitation. Gygi
introduced isotope coded affinity tags (ICAT) in which
isotypical and different biotin-containing moieties are
conjugated to cysteine residues from two different pep-
tide samples to quantitate the mixture of proteins [19].
This technique has been applied successfully to the
detection of membrane proteins [20]. Shotgun proteo-
mics combined with stable isotope labeling or label-free
methods are effective in achieving absolute or relative
protein quantification [21].
Many new proteomics techniques have been devel-
oped, such as iTRAQ (multiplexed isobaric tagging tech-
nology), protein chip, SELDI-TOF-MS (surface
enhanced laser desorption/ionization of flight mass
spectrometry), and SILAC (stable isotope labeling by
amino acids in cell culture) [22-24]. Ultimately, the field
of proteomics, with its depth and fast pace of investiga-
tion, has a tendency to combine multiple techniques so
as to best utilize the benefits of each technique.
Perspective on human disease and mitochondrial
comparative proteomics
Applications of mitochondrial proteomics have shed
some light on the diagnosis and treatment of many dis-
eases associated with mitochondria. In addition, com-
parison of mitochondrial proteome from healthy and
diseased tissues could result in the identification of bio-
markers for the early diagnosis and pathologies con-
cerned with mitochondrial dysfunction (Table 1).
Nervous System
Because the brain is considerably complex and hclewgl-
nouo caccine organism, the orthodox empirical methods
cannot meet the need to investigate the brain’s constitu-
tion and function. The complexity of the nervous system
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Organ Disease
(Researcher)
Analytical
method
Major proteins identified Functional
distribution
Primary Significance
Up-regulated Down-regulated
Nervous
system
Alzheimer’s
disease (AD)
(Lovell MA.)
ICAT, 2D-
LC/MS/MS
ATP synthase alpha
chain
OXPHOS Cells undergoing Aß -mediated
apoptosis increase synthesis of
proteins essential for ATP
production and efflux to maintain
metabolic functions.
Pyruvate kinase, M1
isozyme
glycolysis
Glyceraldehyde
3 phosphate
dehydrogenase
energy production
Cofilin control of actin
polymerization/
depolymerization
Na+/K +
-transporting ATPase
a-3 chain
ATP production
VDAC 1 and 3 apoptosis
Dihydropyrimidinase-
related protein-1
(DRP-1)
axon guidance,
invasive growth
and cell migration
Multiple
sclerosis (MS)
(Broadwater L.)
SELDI-TOF-
MS
Cytochrome c
oxidase subunit
5b (COX5b)
component of
Complex IV of the
electron transport
chain
Proteins identified would be used
as neuroprotective therapeutic
targets for MS.
Hemoglobin b-chain oxygen transport
Myelin basic protein
(MBP)
component of the
myelin membrane
in the CNS
Creatine kinase (CKB) creatine metabolic
process
Neural
degeneration
(Pienaar IS.)
2DE, ESI-
QUADTOF/
MS
Protein disulfide
isomerase (PDI)
folding Alteration of mitochondrial
function may contribute to the
beneficial effects associated with
statin use.
Heat shock proteins protein assembly
and folding
Dehydrogenase
antiporter
transportation
Alpha-internexin
(NF66)
cell differentiation,
morphogenesis of
neurons
Protein-tyrosine
receptor type F
polypeptide
interacting protein
(PTPRF)
cell adhesion
receptor
Neuronal-specific
enolase (NSE)
energy
metabolism
Variation in ATP
synthase, D chain
energy
metabolism
Alpha-enolase-1
(ENO1)
glycolysis, growth
control, hypoxia
tolerance and
allergic responses
Guanine nucleotide-
binding proteins (G-
proteins)
signal
transduction
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Cardiovascular
system
Ischemia-
induced cardiac
injury (Kim N.)
2-DE,
MALDI-
TOF-MS
Prohibitin cell cycle Proteomic analysis provides
appropriate means for identifying
cardiac markers for detection of
ischemia-induced cardiac injury.
VDAC apoptosis
Contractile
dysfunction
(Essop MF.)
2D-PAGE,
ESI-Q-TOF
ATP synthase D
chain
OXPHOS Decreased contractile protein
levels may contribute to the
contractile dysfunction of hearts
from diabetic mice.
Ubiquinol
cytochrome-C
reductase core
protein 1
electron transport
Electron transfer
flavoprotein
subunit a
electron transport
Liver disease
Acetaminophen
(APAP) affected
the liver (Ruepp
SU.)
2D-DIGE,
MALDI-
TOF-MS
HSP10 and HSP60 protein assembly
and folding
APAP toxicity was a direct action
of its known reactive metabolite
NAPQI, rather than a
consequence of gene regulation.
Heat shock 70 kDa
protein 9, (GRP75)
transporters and
channels
High-fat diet
induces hepatic
steatosis
(Eccleston HB.)
2D-IEF/
SDS-PAGE
uMUP-VIII major
urinary protein
pheromone
communication
(only in rodents)
HFD causes steatosis, alters NO
metabolism, and modifies the
liver mitochondrial proteome,
thus, NO may play an important
role in the processes responsible
for NAFLD.
Thiosulfate
sulfurtransferase
cyanide
detoxification, role
in iron-sulfur
centers, sulfane
metabolism
3-hydroxy-3-
methylglutaryl-
CoA synthase 2
(HMG-CoA
synthase)
catalyzes the
condensation of
acetoacetyl CoA
and acetone step
in ketogenesis
Succinate
dehydrogenase
subunit a (SDH-A)
catalyzes the
oxidation of
succinate to
fumarate,
flavoprotein
ATP synthase F1
a and b subunits
OXPHOS
Skeletal muscle
Hypoxia-
induced
changes in rat
skeletal muscle
(De Palma S.)
2D-DIGE,
HPLC ESI-
MS/MS
Hypoxia inducible
factor 1 (HIF-1R)
transcription In vivo adaptation to hypoxia
requires an active metabolic
switch.
Pyruvate
dehydrogenase
kinase 1 (PDK1)
regulation of
glucose
metabolism
Mitochondrial
dihydrolipoamide
dehydrogenase
branched chain
family amino acid
catabolic process
Succinyl CoA
ligase a chain
tricarboxylic acid
cycle
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of synapses. Moreover, because the brain is a vital organ
with massive energy consumption and can only utilize
the energy produced from the process of anaerobic gly-
colysis, the role of mitochondriais very considerable in
this tissue.
A series of studies have identified an abundance of
alterations of in mitochondrial protein levels. To
demonstrate that mutations in mitochondrial tRNA
would affect the pattern of mitochondrial proteins,
Rabilloud et al found a number of proteins in sibling
hybrid cell lines using proteomic methods [25]. Two
proteins that exhibited obvious large quantitative
decreases were identified as nuclear-encoded subunits
of cytochrome c oxidase. This finding clearly demon-
strated a linkage between the effects of mutations in
mitochondrial tRNA genes and the steady-state level of
nuclear-encoded proteins in mitochondria. Alzheimer’s
disease (AD) is a fatal progressive neurodegenerative
disorder whose etiology is unkown until now. Mito-
chondria may play a crucial role in the pathogenesis of
AD. Chou and his colleagues analyzed the differential
mitochondrial protein profile in the cerebral cortices
of 6-month-old male 3 × Tg-AD (which harbor muta-
tions in three human transgenes) and non-transgenic
mice. Certain proteins which involved in a wide variety
of metabolic pathways, such as the citric acid cycle,
oxidative phosphorylation, pyruvate metabolism, and
glycolysis, ect, were dysregulated in 3 × Tg-AD cor-
tices. Interestingly, these alterations in the mitochon-
drial proteome occurred before the development of
significant amyloid plaques and neurofibrillary tangles,
indicating that mitochondrial dysregulation is an early
event in AD [26]. In addition, the potential role of
amyloid beta peptide (Aß)-mediated cell death in AD
has been extensively investigated both in transgenic
animal models and in neuron culture models. Lovell et
al quantitatively measured changes in mitochondrial
proteins of primary rat cortical neuron cultures
exposed to Aß [27]. Ten proteins that were signifi-
cantly altered in Aß-treated cultures were identified,
including sodium/potassium-transporting ATPase,
cofilin, dihydropyrimidinase, pyruvate kinase and vol-
tage-dependent anion channel 1 (VDAC1). Elevations
in the levels of proteins associated with energy produc-
tion indicated that cells undergoing Aß-mediated
apoptosis increased the synthesis of proteins essential
for ATP production and efflux in an attempt to main-
tain metabolic function. Another similar study with Aß
was reported by Gillardon [28]. They analyzed pro-
teome changes in synaptosomal fractions from Tg2576
mice that over-express mutant human amyloid precur-
sor protein (K670N, M671L) and from their non-trans-
genic littermates. Altered expression of certain
proteins, such as heat shock protein 70 and changes in
the subunit composition of the respiratory chain com-
plexes I and III were identified. They concluded that
mitochondria are early targets of Aß aggregates, and
that elevated Aß might impair mitochondrial functions,
thus providing a self-amylifying toxic mechanism.
Another comparative proteomic investigation about
neurodegenerative diseases was reported by Fu [29].
The expression of mitochondrial proteins involved in
mitochondrial membrane potential, ATP production,
and neuronal cell death was down-regulated after
treatment of cerebellar granule neurons with bis(7)-
tacrine. Thus, bis(7)-tacrine might be a beneficial agent
for the treatment of neurodegenerative diseases. Pie-
naar and coworkers conducted a behavioral and quan-
titative mitochondrial proteomic analysis on the effects
of simvastatin on a rat model of neural degeneration.
Twenty-four mitochondrial proteins were identified in
relative abundance after simvastatin treatment. Then
they validated whether simvastatin was capable of
altering sensorimotor function in a mitochondrial
toxin-induced animal model. Rats were pre-treated
with simvastatin for 14 days followed by a single uni-
hemispheric injection of rotenone(a mitochondrial
complex I inhibitor). The results showed that simvasta-
tin improved motor performance in rotenone-infused
rats. The results of behavioral and quantitative proteo-
mic analysis are consistent and further exploration of
these changes may identify promising bio-targets for
degenerative disorders [30].
Table 1 Overview of diseases associated with the mitochondrial proteome (Continued)
Lifestyle on the
aging
alterations
(Alves RM.)
2-DE,
MALDI-
TOF/TOF
NADH
dehydrogenase
[ubiquinone] 1 a
subcomplex subunit
4
oxidative
phosphorylation
Lifestyle is a key modulator for
preventing aging-induced protein
expression and functionality in
mitochondria.
Creatine kinase signal
transduction
Superoxide dismutase
[Mn], mitochondrial
redox
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generative disease of the central nervous system that
results in progressive physical and cognitive disability.
Broadwater et al utilized SELDI-TOF-MS to characterize
the mitochondrial proteome in postmortem MS and
control cortex. Peptide fingerprint mapping unambigu-
ously identified four proteins, including cytochrome c
oxidase subunit 5b (COX5b), the brain specific isozyme
of creatine kinase, hemoglobin b-chain, and myelin
basic protein (MBP), that could be used as neuroprotec-
tive therapeutic targets for MS [31].
As a whole, studies on the mitochondrial proteome of
the nervous system provide a broader insight on various
fractions of brain and the same fractions under various
physiological and pathological states. However, most of
the investigations are currently based on animal models
because of the difficulty to obtain brain samples from
humans. The results from the proteomics studies
revealed that mitochondrial structural and functional
alterations appear to play an important role in nervous
system diseases.
Cardiovascular System
Cardiovascular diseases have been the main “killer” in
human beings, and thus, early diagnosis and treatment is
imperative. Mitochondria are the major site of substrate
oxidation in cardiomyocytes. Furthermore, oxidative
stress plays a key role in heart diseases, and mitochondria
are considered a principle source and target of reactive
oxygen species (ROS) [32]. ROS can damage cellular
lipids, proteins, and DNA, thereby disrupting their nor-
mal functions. Several large-scale studies have systemati-
cally reported some notable biological and medical
insights into the mitochondrial proteome in the cardio-
vascular system as described below.
The ischemic heart is an important model for
researchers studying the cardiovascular diseases. Until
now, most of the findings from comparative mitochon-
drial proteomic studies were associated with the respira-
tory chains and energy metabolism in the ischemic
heart. For example, Kim et al detected regional differ-
ences in protein expression levels from mitochondrial
fractions of control, ischemia-reperfusion (IR), and
ischemic preconditioned (IPC) rabbit hearts [8]. In addi-
tion, Essop and colleagues investigated the alterations in
the mitochondrial proteome in a mouse model of obe-
sity/type 2 diabetes. Several proteins that play role in
mitochondrial energy metabolism, including ATP
synthase D chain, ubiquinol cytochrome-C reductase
core protein 1, and electron transfer flavoprotein subu-
nit alpha, were identified to have changes in protein
levels [33].
Mitochondria play a crucial role in the regeneration of
antioxidants through the production of reducing
equivalents and are responsible for the vast majority of
ATP production within most cells and higher organisms.
Hunzinger [34] employed a proteomics approach to
investigate the role of ROS on bovine heart and identi-
fied two specific N-formylkynurenine modifications of
aconitase-2, which is an enzyme that plays an important
role in mitochondrial aging. Additional investigations on
these two modifications might identify them as potential
protein biomarker signatures for ROS. Serious and/or
long-term ischemia will lead to heart infarction. It has
been proposed that in ischemic preconditioning (PC) or
pharmacological preconditioning, the GSK-3 (glycogen
synthase kinase-3) inhibitor AR-A014418 will initiate
signaling cascades that converges on mitochondria and
results in cardioprotection. Therefore, Wong et al uti-
lized 2D-DIGE coupled with Blue Native-PAGE to con-
firm their hypothesis that PC and pharmacological
preconditioning similarly altered mitochondrial signaling
complexes III, IV, and V. The altered expression levels
of electron transport complexes obtained from the
above-mentioned study should impart important impli-
cations for the mechanism of cardioprotection [35].
In short, most of the mitochondrial proteomics studies
in cardiovascular diseases were associated with ROS. It
is well known that ischemia and aging are the main
causes of cardiovascular diseases, which can result in
the release of ROS. Therefore, ROS are still a primary
focus when researchers investigate cardiovascular dis-
ease. Targeting on ROS might be applicable to the treat-
ment of many cardiovascular problems in the future.
Cancer and Hematological Diseases
The mitochondrial proteome has altered expression
levels and structures in cancer cells, as well as that in
cells altered simulide when stimulated by various treat-
ments (Table 2).
Chevallet et al [36] employed a comparative study on
the osteoscrcoma 143B cell line and its Rho-0 counter-
part (devoid of mitochondrial DNA). Quantitative differ-
ences were found between these cell lines in factors,
such as the respiratory complexes subunits, the mito-
chondrial translation apparatus, mitochondrial ribosomal
proteins, and the proteins with roles in the ion and pro-
tein import system. They also found that proteins
involved in apoptosis control and import systems were
differentially regulated in Rho-0 mitochondria. To iden-
tify proteins involved in a retrograde response and their
potential role in tumorigenesis, Kulawiec [37] conducted
a comparative proteomic analysis using the two cell
lines noted above and the parental cell line. They found
that subunits of complex I and III, molecular chaper-
ones, and a protein involved in cell cycle control were
down-regulated and that inosine 5’-monophosphate
dehydrogenase type 2 (IMPDH2), which is involved in
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proteomics
Disease Cell lines/
Treatment
Analytical
methods
Up-regulated proteins Down-regulated
proteins
Functions Primary significance
Hematologic
diseases
AML NB4/
camptothecin
2-DE,
MALDI-
TOF/TOF
Far upstream
element-binding
protein-1 (FUBP1)
transcription,
translation, and
degradation of
proteins
Provided new insights for
systematically understanding
the mechanisms of the
camptothecin-induced
apoptosis.
Heterogeneous
nuclear
ribonucleoprotein A1
(HNRPA1)
mRNA processing
Heterogeneous
nuclear
ribonucleoproteins
C1/C2 (HNRPC)
modified with
shift of pI and
MW
26S protease regulatory
subunit 6A (PSMC3)
degradation
Proteasome subunit alpha
type (PSMA)-1, 2, 6
degradation
Non-
Hodgkin’s
lymphoma
Raji/
Adramycin
DIGE, LTQ-
ESI-MS/MS
ATP synthase d chain,
mitochondrial (ATPQ,
ATP5H)
OXPHOS Specific mitochondrial
proteins were uniquely
susceptible to alterations in
abundance following
exposure to ADR and carry
implications for the
investigation of therapeutic
and prognostic markers.
Prohibitin (PHB) cell cycle
Heat shock 70 kDa protein
9 precursor (HSPA9)
transporters and
channels
Isoform 4 of
Mitochondrial ATP-
binding cassette sub-
family B member 6
(ABCB6)
protein synthesis
and degradation
Superoxide
dismutase [Mn],
mitochondrial
precursor (SOD2)
redox
Other solid
tumors
Osteosarcoma 143B/devoid
of
mitochondrial
DNA
2-DE,
MALDI-
TOF/MS
NADH-ubiquinone
oxidoreductase 75
kDa subunit
respiratory
complexes
subunits
Demonstrates the pleiotropic
effects of mtDNA alterations
and also gives valuable
markers for the study of the
mitochondrial-cytosolic
coordination.
Mitochondrial 28S
ribosomal protein S2
mitochondrial
translation
apparatus
Mitochondrial import
inner membrane
translocase subunit
Tim9
protein transport
Succinyl-CoA ligase
(ADP-forming) beta-
chain
energy
production
Jiang and Wang Journal of Hematology & Oncology 2012, 5:11
http://www.jhoonline.org/content/5/1/11
Page 7 of 13nucleotide biosynthesis, was up-regulated in r0 cells.
Retrograde proteins identified in these studies might be
useful as therapeutic targets due to their roles as poten-
tial tumor suppressors or oncogenes involved in
carcinogenesis.
Several investigations on other tumor mitochondrial
proteome were also conducted recently. Regarding
breast cancer, Strong et al [38] identified differentially
expressed proteins in the mitochondria of MCF-7
human breast cancer cells that were selected for resis-
tance to adriamycin accompanied by verapamil. Those
identified proteins were mainly involved in apoptosis,
heme synthesis, fatty acid oxidation, and oxidative phos-
phorylation. The implications of these changes in pro-
tein levels are relevant to mechanisms of drug
resistance. Craven [39] compared the mitochondrial pro-
teome in VHL (von Hippel Lindau, a tumor suppressor
gene)-defective RCCs (renal cell carcinomas), which
were transfected with either a control vector or wild-
type VHL. That study showed that the mitochondrial
protein ubiquinol cytochrome c reductase complex core
protein 2 was up-regulated and a form of septin 2 was
Table 2 Progress in the treatment of hematologic diseases and solid tumor based on mammalian mitochondrial pro-
teomics (Continued)
Breast cancer
MCF-7/
resistance to
adriamycin
accompanied
by verapamil
2-DE,
QqTOF-ESI-
MS/MS
Cofilin control of
polymerization/
depolymerization
of actin
Implications of the changes
are considered with respect
to drug resistance.
CoproporphyrinogenIII
(CPO)
heme
biosynthesis
3.2 trans-enoyl CoA
isomerase
fatty acid
oxidation
Adenylate kinase 2 ATP, OXPHOS
Renal cell
carcinomas
UMRC2, 786-0
and RCC4/VHL
(von Hippel
Lindau)-
defective
2-DE, MS Heat shock 70 kDa protein transporters and
channels
Increased expression of septin
2 is a common event in RCC
and protein modification may
also alter septin 2 function in
a subset of tumors.
10-formyltetrahydrofolate
dehydrogenase
one-carbon
metabolism
Phosphoribosylglycinamide
formyltransferase
purine
biosynthesis
Ubiquinol cytochrome c
reductase complex core
protein 2
electron transport
Elongation factor 2 protein
biosynthesis
Phosphofructokinase
isozyme C
glycolysis
Thioredoxin
reductase
differentiation,
electron transport
Septin 2 cell cycle
Prostate
cancer
LNCaP/
somatostatin
VDAC1, VDAC2 apoptosis Somatos might be able to
curb the progression of
advanced prostate cancer.
Peroxiredoxin 2
(PRDX2)
antioxidant
activity
Translationally
controlled tumor
protein (TCTP)
calcium binding
and microtubule
stabilization.
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was up-regulated in 12/16 RCCs. Thus, increased
expression of septin 2 is a common event in RCC, and
protein modification may also change the function of
septin 2 in a subset of tumors. Zhao et al [40] incubated
the LNCaP cell-line with sms (somatostatin)14/smsds
and demonstrated that proteins with roles in apoptosis
were both up-regulated (VDAC1, VDAC2) and down-
regulated (PRDX2, TCTP). Sms/smsdx was believed to
trigger the up-regulation of catalytic mitochondrial pro-
teins and seemed to affect apoptosis-related proteins.
Only a few studies have reported the effects of hema-
tological disease on the mitochondrial proteome. Yu et
al [41] analyzed protein expression profiles of fractio-
nated nuclei, mitochondria, crude endoplasmic reticu-
lum, and cytosols of the NSC606985-induced apoptotic
AML cell line NB4 cells using 2-DE combined with
MALDI-TOF/TOF. They identified 90 unique deregu-
lated proteins that contributed to multiple functional
activities including DNA damage repair, chromosome
assembly, and mRNA processing as well as biosynthesis,
modification, and degradation of proteins. More inter-
estingly, several oxidative stress-related proteins that
were shown up-regulated were localized in mitochon-
dria, while proteins that were up-regulated with roles in
glycolysis were mainly localized in the nuclei. Their dis-
coveries shed new insights for systematically under-
standing mechanisms of the camptothecin-induced
apoptosis. In our previous study, we investigated mito-
chondrial proteome alterations in NHL Raji cells
exposed to adriamycin. Our results showed that 34 pro-
teins were down-regulated and 3 proteins up-regulated
when the study group was compared with the control
group. The differentially expressed proteins play roles in
many cellular functions, including redox, DNA repair,
cell cycle regulation, transporters and channels, and
OXPHOS. Furthermore, HSP70, ABCB6, and PHB iden-
tified in this study may be closely related to chemoresis-
tance, and this potentially serving as chemotherapeutic
targets for NHL [42].
Collectively, studies on mitochondrial proteomics will
further investigate into cancerous biological behavior
and mechanisms of antineoplastic agents. Subsequently,
improved diagnosis, and treatment methods, and new
treatment targets will likely be obtained.
Other Diseases
Mitochondrial proteomics also revealed a number of sig-
nificant findings in other diseases, such as hepatopathy,
placenta changes, and skeleton muscle disease.
The liver is an important organ that has an abundance
of mitochondria. Ruepp [43] investigated the effects of
acetaminophen (APAP) in the liver on the proteomic
level and found that chaperone proteins HSP10 and
HSP60 were readily decreased by half in mitochondria
at different doses of APAP. The decrease of ATP
synthase subunits levels and b-oxidation pathway pro-
teins indicated a loss of energy production. Douette and
coworkers [44] compared mitochondrial protein patterns
in wild-type and steatosis-affected liver and identified 58
proteins exhibiting significantly different levels in these
two samples. Interestingly, major proteins that regulate
the generation and consumption of the acetyl-CoA pool
were dramatically changed during steatosis. Further-
more, many proteins involved in the response to oxida-
tive stress were also affected. Lee [45] assessed global
protein expression profiles in term placentas from scNT
(somatic cell-derived nuclear transfer)-derived and con-
trol animals. Forty-three unique proteins were identified,
including such proteins play critical roles in the apopto-
sis signaling pathways as 14-3-3 proteins were up-regu-
lated in scNT-derived when compared to the Annexin V
in control animals group. Their results suggested that
placental insufficiency in scNT-derived placentas may be
due to apoptosis, induced in part by the down-regula-
tion of 14-3-3 proteins and the up-regulation of
Annexin V. De Palma [46] investigated the hypoxia-
induced changes of rat skeletal muscle and indicated
that proteins involved in the TCA cycle, ATP produc-
tion, and electron transport are down-regulated, whereas
glycolytic enzymes and deaminases involved in ATP and
AMP production were up-regulated. The up-regulation
of the hypoxia markers hypoxia inducible factor 1 (HIF-
1a) and pyruvate dehydrogenase kinase 1 (PDK1) sug-
gested that in vivo adaptation to hypoxia requires an
active metabolic switch. Eccleston et al hypothesized
that chronic exposure to a high fat diet (HFD) would
modify the liver mitochondrial proteome, which might
ultimately compromise mitochondrial function. Using
two-dimensional isoelectric-focusing (IEF)/SDS-PAGE,
22 proteins which played roles of oxidative phosphoryla-
tion, lipid metabolism, sulfur amino acid metabolism,
and chaperone proteins, showed altered levels as a con-
sequence of the HFD. These proteomic studies were
complemented by measuring mitochondrial ROS pro-
duction and assessing the impact of a HFD on the levels
of two key enzymes involved in maintaining tissue NO:
arginase1 and endothelial nitric oxide synthase (eNOS)
[47].
Alves [48] studied the influence of lifestyle on the
aging alterations in skeletal muscle mitochondrial pro-
teins with 2-DE combined MALDI-TOF/TOF. Their
results confirmed that certain mitochondrial proteins,
particularly those play role in the citric acid cycle and as
OXPHOS components, showed increased carbonylation.
The data obtained indicated that lifestyle was a key
modulator for preventing the expression and functional-
ity of aging-induced proteins in mitochiondria.
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regarding the important role of mitochondria in the reg-
ulation of apoptosis, energy metabolism, and electron
transfer. Mitochondrial proteomics have been performed
in various fields and have gained considerable achieve-
ments. Mitochondrial proteomics are currently the most
popular area of subcellular proteomics being
investigated.
Challenges
Proteomic techniques are becoming more and more
advanced established. However, the study of proteins is
not similar to that of DNA and RNA. First, proteins
have more complicated two- and three-dimensional
structures, and second, proteins cannot be amplified like
DNA. Protein structure can be easily altered, but cannot
be easily detected if the amount is too small. As far as
the mitochondrial proteome is concerned, many ques-
tions remain unresolved.
(1) The isolation and purification of mitochondria: At
present, the well-recognized method for isolating mito-
chondria from tissues or cells is Taylor’s classic
method, which uses sucrose density gradient centrifu-
gation [3]. However, this method requires ultracentri-
fugation and is time-consuming. Many efforts have
been made to improve Taylor’s method [49,50].
Furthermore, special kits for mitochondria isolation
have been put onto the market that do not require
ultracentrifugation and are more time-efficient. The
purity of the mitochondria isolated by these kits has
been shown to be fairly good [51].
(2) Limitations of 2-DE: 2-DE is not good for solving
many problems, such as how to remove high abundant
proteins or how to isolate proteins with extreme alkali-
nity or acidity. With regard to mitochondria, a large
proportion of the proteins have an extreme alkaline iso-
electric point (pI). As a result, they are unable to be
resolved by isoelectric focusing due to endo-osmotic
effects upon the pH gradient [12]. In fact, some proteins
have a pI that is too alkaline to be visible on typical
wide range (pH 3-10) immobilized pH gradient (IPG)
strips. For example, the pI of cytochrome c is 10.3 [13].
Although 2-DE is a powerful instrument, for this pur-
pose, it still needs further improvement or replacement
by other more effective techniques.
(3) The limitation of bioinformatic tools and the mito-
chondrial database: To meet the bioinformatic require-
ments of large-scale proteomic studies, many
researchers have tried to use series-based attempts to
overcome the shortcomings of single proteomic techni-
ques. White and his colleagues use five parallel metho-
dological approaches, ((i) peptide-centric 1-DLC, (ii)
peptide-centric 2-DLC, (iii) protein-centric 1-DLC, (iv)
protein-centric 2-DLC, and (v) subfractionated
mitochondria) to improve the coverage of the partially
annotated rabbit mitochondrial proteome prior to mass
spectrometry. They found that the overall coverage of
the cardiomyocyte mitochondrial proteome was
improved by this parallel approach where the total num-
ber of nonredundant peptides or proteins was nearly 2
fold and more than 1.5-fold, respectively, greater than
that by any single technique. They assumed that obser-
vation of proteins across multiple technologies improves
the likelihood of true mitochondrial localization [52].
Furthermore, for the homologous proteins and redun-
dant entries in the sequence database, one of the chal-
lenges in protein identification is that many peptides
can be matched to several different proteins [53]. It
would be helpful to use more than one database search
engine when analyzing complex protein mixtures from
the same raw data [54]. However, manual comparison
and analysis of large database search results are labor-
ious and time-consuming. Furthermore, most of these
tools can utilize data from only a few database search
engines, and currently, there are no free tools that could
be used to combine protein identification results from
paragon with results from other search engines. Thus, it
is necessary to develop fast, accurate, and easy-to-use
tools to integrate and compare protein identification
results.
The insufficiency of mitochondrial databases is
another problem. The first attempt to build a 2-DE
database of the mitochondrial proteome was performed
by Rabilloud [55]. However, that database was consid-
ered both incomplete and inefficient. Now, a large
amount of new data has been added into databases such
as SWISS-PROT, NCBI, MITOMAP, mtDB, hmtDB,
MitoP2, MigDB, and MitoProteome [56-58]. MitoP2 is
the most comprehensive database for the mitochondrial
proteome and includes a more complete set of these
mitochondrial proteins for human (624), mouse (615),
and yeast (522) for each of these organisms respectivly
[58]. However, due to the emergence of this new sub-
ject, the databases are still very insufficient and require
more exploration for enrichment.
(4) Clinical applications: Many studies on the mito-
chondrial proteome have been reported, and how to uti-
lize the findings in the clinic to gain the maximum
benefits is still a large problem. Only a few of identified
biomarkers have been currently used by clinicians as
diagnostic and/or prognostic factors [59,60]. Novel bio-
markers identified by proteomics can be developed for
increased precision in diagnosis, therapy sensitivity, pro-
gression, and prognosis evaluation of disease. Informa-
tion on bioinformatics obtained from proteomic
analyses is still scarce. These challenges have not been
overcome by the existing methods and they have
become a limitation to further advancement.
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together in pathways and complexes is still a significant
challenge. Many biomarkers found in proteomic studies
were conformed to be involved in various mitochon-
drial-associated signaling pathways, including apoptosis,
cell cycle, and DNA repair [61,62]. Many validation tests
using methods such as RNAi, protein-protein interaction
mapping, and computational predictions should be
linked to the future investigations [63,64].
Standardizing these current proteomic experiment in
terms of sample collection, storage and processing as
well as bio-informatics and statistical analysis between
various centers is serious necessary [65]. Future perspec-
tives will focus on the clinical applications of these bio-
markers to improve diagnostic accuracy and prognostic
precision. Thus, more intimate, repeatable, and verifiable
experiments are eagerly awaited.
Conclusions
The emergence of comparative proteomics enables us to
investigate the mitochondrial proteome in a more com-
prehensive and effective manner. The results of mito-
chondrial proteomics provide a better understanding of
the pathogenesis associated with mitochondria and gen-
erate promising therapeutic targets. However, these
novel findings are most unlikely to completely reflect
the true state of mitochondria because some biological
information may be lost or altered during the course
that mitochondria are isolated from the cell. Moreover,
the mitochondrial proteome alterations in animal mod-
els may differ from those of human. Therefore, more
efforts are needed to look at the validation across spe-
cies carefully. Validation and utilization of clinically
associated proteomic biomarkers would be helpful to
the diagnosis, effective treatment, and prognosis evalua-
tion of mitochondria-mediated diseases. Thus, the for-
mulation of personalized medicine may become a reality
in the future. This is an open-ended exploration, and
more achievements are anticipated in the near future.
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